Scios, Novo Nordisk deal

SCIO granted Novo Nordisk an exclusive license to SCIO's insulinotropin technology, which is in Phase II trials to treat Type II diabetes. In June, the companies announced a three-month option agreement for the technology (see BioCentury June 3). Insulinotropin (glucagon-like-peptide-1) is a naturally occurring peptide hormone that stimulates insulin release in response to increases in blood sugar levels. The agreement includes several U.S. and European patents covering insulinotropin, related compounds, and their use in treating Type II diabetes. ...